NT5E (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "NT5E" in English language version.

Last modified: 11:48:46, 11 August 2026 (UTC)

Ref.Un. Ref.Website

Global rank English rank

3929nih.gov

5^th place

2116doi.org

2^nd place

62ensembl.org

630^th place

326^th place

33semanticscholar.org

15^th place

8^th place

11omim.org

3,900^th place

3,720^th place

11worldcat.org

4^th place

11healio.com

low place

doi.org (Global: 2^nd place; English: 2^nd place)

Misumi Y, Ogata S, Ohkubo K, Hirose S, Ikehara Y (August 1990). "Primary structure of human placental 5'-nucleotidase and identification of the glycolipid anchor in the mature form". European Journal of Biochemistry. 191 (3): 563–9. doi:10.1111/j.1432-1033.1990.tb19158.x. PMID 2129526.
Allard B, Cousineau I, Spring K, Stagg J (January 2019). "Chapter Fifteen - Measurement of CD73 enzymatic activity using luminescence-based and colorimetric assays". In Rudqvist L, Galluzzi NP (eds.). Methods in Enzymology. Vol. 629. Academic Press. pp. 269–289. doi:10.1016/bs.mie.2019.10.007. ISBN 978-0-12-818671-8. PMID 31727245. S2CID 208035622.
Dong K, Gao ZW, Zhang HZ (December 2016). "The role of adenosinergic pathway in human autoimmune diseases". Immunologic Research. 64 (5–6): 1133–1141. doi:10.1007/s12026-016-8870-2. PMC 5126201. PMID 27665459.
Kordaß T, Osen W, Eichmüller SB (2018-04-18). "Controlling the Immune Suppressor: Transcription Factors and MicroRNAs Regulating CD73/NT5E". Frontiers in Immunology. 9: 813. doi:10.3389/fimmu.2018.00813. PMC 5915482. PMID 29720980.
Kordaß T, Osen W, Eichmüller SB (2018). "Controlling the Immune Suppressor: Transcription Factors and MicroRNAs Regulating CD73/NT5E". Frontiers in Immunology. 9: 813. doi:10.3389/fimmu.2018.00813. PMC 5915482. PMID 29720980.
St Hilaire C, Ziegler SG, Markello TC, Brusco A, Groden C, Gill F, et al. (February 2011). "NT5E mutations and arterial calcifications". The New England Journal of Medicine. 364 (5): 432–42. doi:10.1056/NEJMoa0912923. PMC 3049958. PMID 21288095.
Sharp J (March 1954). "Heredo-familial vascular and articular calcification". Annals of the Rheumatic Diseases. 13 (1): 15–27. doi:10.1136/ard.13.1.15. PMC 1030367. PMID 13149051.
Knight JS, Mazza LF, Yalavarthi S, Sule G, Ali RA, Hodgin JB, et al. (2018). "Ectonucleotidase-Mediated Suppression of Lupus Autoimmunity and Vascular Dysfunction". Frontiers in Immunology. 9: 1322. doi:10.3389/fimmu.2018.01322. PMC 6004379. PMID 29942314.
Zhu J, Zeng Y, Li W, Qin H, Lei Z, Shen D, et al. (February 2017). "CD73/NT5E is a target of miR-30a-5p and plays an important role in the pathogenesis of non-small cell lung cancer". Molecular Cancer. 16 (1) 34. doi:10.1186/s12943-017-0591-1. PMC 5291990. PMID 28158983.
Yu M, Guo G, Huang L, Deng L, Chang CS, Achyut BR, et al. (January 2020). "2B-mediated feedforward circuit enforces an immune checkpoint". Nature Communications. 11 (1): 515. doi:10.1038/s41467-019-14060-x. PMC 6981126. PMID 31980601.
Tripathi A, Lin E, Nussenzveig R, Yandell M, Pal SK, Agarwal N (2019-05-20). "NT5E expression and the immune landscape of prostate cancer (PC): An analysis from The Cancer Genome Atlas database". Journal of Clinical Oncology. 37 (15_suppl) e16591. doi:10.1200/JCO.2019.37.15_suppl.e16591. ISSN 0732-183X. S2CID 190909472.
Bazhin AV, Amedei A, Karakhanova S (2018). "Editorial: Immune Checkpoint Molecules and Cancer Immunotherapy". Frontiers in Immunology. 9: 2878. doi:10.3389/fimmu.2018.02878. PMC 6290335. PMID 30568661.
Zhang F, Luo Y, Shao Z, Xu L, Liu X, Niu Y, et al. (April 2016). "MicroRNA-187, a downstream effector of TGFβ pathway, suppresses Smad-mediated epithelial-mesenchymal transition in colorectal cancer". Cancer Letters. 373 (2): 203–13. doi:10.1016/j.canlet.2016.01.037. PMID 26820227.
Leone RD, Emens LA (June 2018). "Targeting adenosine for cancer immunotherapy". Journal for Immunotherapy of Cancer. 6 (1) 57. doi:10.1186/s40425-018-0360-8. PMC 6006764. PMID 29914571.
Antonioli L, Yegutkin GG, Pacher P, Blandizzi C, Haskó G (February 2016). "Anti-CD73 in cancer immunotherapy: awakening new opportunities". Trends in Cancer. 2 (2): 95–109. doi:10.1016/j.trecan.2016.01.003. PMC 4800751. PMID 27014745.
Ghalamfarsa G, Kazemi MH, Raoofi Mohseni S, Masjedi A, Hojjat-Farsangi M, Azizi G, et al. (February 2019). "CD73 as a potential opportunity for cancer immunotherapy". Expert Opinion on Therapeutic Targets. 23 (2): 127–142. doi:10.1080/14728222.2019.1559829. PMID 30556751. S2CID 58767911.

ensembl.org (Global: 630^th place; English: 326^th place)

may2017.archive.ensembl.org

GRCh38: Ensembl release 89: ENSG00000135318 – Ensembl, May 2017
GRCm38: Ensembl release 89: ENSMUSG00000032420 – Ensembl, May 2017

healio.com (Global: low place; English: low place)

"Anti-CD73 antibody agent appears safe, shows promise in advanced cancers". HemOncToday. Healio. 8 November 2019.

nih.gov (Global: 5^th place; English: 5^th place)

pubmed.ncbi.nlm.nih.gov

Misumi Y, Ogata S, Ohkubo K, Hirose S, Ikehara Y (August 1990). "Primary structure of human placental 5'-nucleotidase and identification of the glycolipid anchor in the mature form". European Journal of Biochemistry. 191 (3): 563–9. doi:10.1111/j.1432-1033.1990.tb19158.x. PMID 2129526.
Allard B, Cousineau I, Spring K, Stagg J (January 2019). "Chapter Fifteen - Measurement of CD73 enzymatic activity using luminescence-based and colorimetric assays". In Rudqvist L, Galluzzi NP (eds.). Methods in Enzymology. Vol. 629. Academic Press. pp. 269–289. doi:10.1016/bs.mie.2019.10.007. ISBN 978-0-12-818671-8. PMID 31727245. S2CID 208035622.
Dong K, Gao ZW, Zhang HZ (December 2016). "The role of adenosinergic pathway in human autoimmune diseases". Immunologic Research. 64 (5–6): 1133–1141. doi:10.1007/s12026-016-8870-2. PMC 5126201. PMID 27665459.
Kordaß T, Osen W, Eichmüller SB (2018-04-18). "Controlling the Immune Suppressor: Transcription Factors and MicroRNAs Regulating CD73/NT5E". Frontiers in Immunology. 9: 813. doi:10.3389/fimmu.2018.00813. PMC 5915482. PMID 29720980.
Kordaß T, Osen W, Eichmüller SB (2018). "Controlling the Immune Suppressor: Transcription Factors and MicroRNAs Regulating CD73/NT5E". Frontiers in Immunology. 9: 813. doi:10.3389/fimmu.2018.00813. PMC 5915482. PMID 29720980.
St Hilaire C, Ziegler SG, Markello TC, Brusco A, Groden C, Gill F, et al. (February 2011). "NT5E mutations and arterial calcifications". The New England Journal of Medicine. 364 (5): 432–42. doi:10.1056/NEJMoa0912923. PMC 3049958. PMID 21288095.
Sharp J (March 1954). "Heredo-familial vascular and articular calcification". Annals of the Rheumatic Diseases. 13 (1): 15–27. doi:10.1136/ard.13.1.15. PMC 1030367. PMID 13149051.
Knight JS, Mazza LF, Yalavarthi S, Sule G, Ali RA, Hodgin JB, et al. (2018). "Ectonucleotidase-Mediated Suppression of Lupus Autoimmunity and Vascular Dysfunction". Frontiers in Immunology. 9: 1322. doi:10.3389/fimmu.2018.01322. PMC 6004379. PMID 29942314.
Zhu J, Zeng Y, Li W, Qin H, Lei Z, Shen D, et al. (February 2017). "CD73/NT5E is a target of miR-30a-5p and plays an important role in the pathogenesis of non-small cell lung cancer". Molecular Cancer. 16 (1) 34. doi:10.1186/s12943-017-0591-1. PMC 5291990. PMID 28158983.
Yu M, Guo G, Huang L, Deng L, Chang CS, Achyut BR, et al. (January 2020). "2B-mediated feedforward circuit enforces an immune checkpoint". Nature Communications. 11 (1): 515. doi:10.1038/s41467-019-14060-x. PMC 6981126. PMID 31980601.
Bazhin AV, Amedei A, Karakhanova S (2018). "Editorial: Immune Checkpoint Molecules and Cancer Immunotherapy". Frontiers in Immunology. 9: 2878. doi:10.3389/fimmu.2018.02878. PMC 6290335. PMID 30568661.
Zhang F, Luo Y, Shao Z, Xu L, Liu X, Niu Y, et al. (April 2016). "MicroRNA-187, a downstream effector of TGFβ pathway, suppresses Smad-mediated epithelial-mesenchymal transition in colorectal cancer". Cancer Letters. 373 (2): 203–13. doi:10.1016/j.canlet.2016.01.037. PMID 26820227.
Leone RD, Emens LA (June 2018). "Targeting adenosine for cancer immunotherapy". Journal for Immunotherapy of Cancer. 6 (1) 57. doi:10.1186/s40425-018-0360-8. PMC 6006764. PMID 29914571.
Antonioli L, Yegutkin GG, Pacher P, Blandizzi C, Haskó G (February 2016). "Anti-CD73 in cancer immunotherapy: awakening new opportunities". Trends in Cancer. 2 (2): 95–109. doi:10.1016/j.trecan.2016.01.003. PMC 4800751. PMID 27014745.
Ghalamfarsa G, Kazemi MH, Raoofi Mohseni S, Masjedi A, Hojjat-Farsangi M, Azizi G, et al. (February 2019). "CD73 as a potential opportunity for cancer immunotherapy". Expert Opinion on Therapeutic Targets. 23 (2): 127–142. doi:10.1080/14728222.2019.1559829. PMID 30556751. S2CID 58767911.

ncbi.nlm.nih.gov

"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
"Entrez Gene: NT5E 5′-nucleotidase, ecto (CD73)".
Dong K, Gao ZW, Zhang HZ (December 2016). "The role of adenosinergic pathway in human autoimmune diseases". Immunologic Research. 64 (5–6): 1133–1141. doi:10.1007/s12026-016-8870-2. PMC 5126201. PMID 27665459.
Kordaß T, Osen W, Eichmüller SB (2018-04-18). "Controlling the Immune Suppressor: Transcription Factors and MicroRNAs Regulating CD73/NT5E". Frontiers in Immunology. 9: 813. doi:10.3389/fimmu.2018.00813. PMC 5915482. PMID 29720980.
Kordaß T, Osen W, Eichmüller SB (2018). "Controlling the Immune Suppressor: Transcription Factors and MicroRNAs Regulating CD73/NT5E". Frontiers in Immunology. 9: 813. doi:10.3389/fimmu.2018.00813. PMC 5915482. PMID 29720980.
St Hilaire C, Ziegler SG, Markello TC, Brusco A, Groden C, Gill F, et al. (February 2011). "NT5E mutations and arterial calcifications". The New England Journal of Medicine. 364 (5): 432–42. doi:10.1056/NEJMoa0912923. PMC 3049958. PMID 21288095.
Sharp J (March 1954). "Heredo-familial vascular and articular calcification". Annals of the Rheumatic Diseases. 13 (1): 15–27. doi:10.1136/ard.13.1.15. PMC 1030367. PMID 13149051.
Knight JS, Mazza LF, Yalavarthi S, Sule G, Ali RA, Hodgin JB, et al. (2018). "Ectonucleotidase-Mediated Suppression of Lupus Autoimmunity and Vascular Dysfunction". Frontiers in Immunology. 9: 1322. doi:10.3389/fimmu.2018.01322. PMC 6004379. PMID 29942314.
Zhu J, Zeng Y, Li W, Qin H, Lei Z, Shen D, et al. (February 2017). "CD73/NT5E is a target of miR-30a-5p and plays an important role in the pathogenesis of non-small cell lung cancer". Molecular Cancer. 16 (1) 34. doi:10.1186/s12943-017-0591-1. PMC 5291990. PMID 28158983.
Yu M, Guo G, Huang L, Deng L, Chang CS, Achyut BR, et al. (January 2020). "2B-mediated feedforward circuit enforces an immune checkpoint". Nature Communications. 11 (1): 515. doi:10.1038/s41467-019-14060-x. PMC 6981126. PMID 31980601.
Bazhin AV, Amedei A, Karakhanova S (2018). "Editorial: Immune Checkpoint Molecules and Cancer Immunotherapy". Frontiers in Immunology. 9: 2878. doi:10.3389/fimmu.2018.02878. PMC 6290335. PMID 30568661.
Leone RD, Emens LA (June 2018). "Targeting adenosine for cancer immunotherapy". Journal for Immunotherapy of Cancer. 6 (1) 57. doi:10.1186/s40425-018-0360-8. PMC 6006764. PMID 29914571.
Antonioli L, Yegutkin GG, Pacher P, Blandizzi C, Haskó G (February 2016). "Anti-CD73 in cancer immunotherapy: awakening new opportunities". Trends in Cancer. 2 (2): 95–109. doi:10.1016/j.trecan.2016.01.003. PMC 4800751. PMID 27014745.

omim.org (Global: 3,900^th place; English: 3,720^th place)

Online Mendelian Inheritance in Man (OMIM): 211800

semanticscholar.org (Global: 15^th place; English: 8^th place)

api.semanticscholar.org

Allard B, Cousineau I, Spring K, Stagg J (January 2019). "Chapter Fifteen - Measurement of CD73 enzymatic activity using luminescence-based and colorimetric assays". In Rudqvist L, Galluzzi NP (eds.). Methods in Enzymology. Vol. 629. Academic Press. pp. 269–289. doi:10.1016/bs.mie.2019.10.007. ISBN 978-0-12-818671-8. PMID 31727245. S2CID 208035622.
Tripathi A, Lin E, Nussenzveig R, Yandell M, Pal SK, Agarwal N (2019-05-20). "NT5E expression and the immune landscape of prostate cancer (PC): An analysis from The Cancer Genome Atlas database". Journal of Clinical Oncology. 37 (15_suppl) e16591. doi:10.1200/JCO.2019.37.15_suppl.e16591. ISSN 0732-183X. S2CID 190909472.
Ghalamfarsa G, Kazemi MH, Raoofi Mohseni S, Masjedi A, Hojjat-Farsangi M, Azizi G, et al. (February 2019). "CD73 as a potential opportunity for cancer immunotherapy". Expert Opinion on Therapeutic Targets. 23 (2): 127–142. doi:10.1080/14728222.2019.1559829. PMID 30556751. S2CID 58767911.

worldcat.org (Global: 4^th place; English: 4^th place)

search.worldcat.org

Tripathi A, Lin E, Nussenzveig R, Yandell M, Pal SK, Agarwal N (2019-05-20). "NT5E expression and the immune landscape of prostate cancer (PC): An analysis from The Cancer Genome Atlas database". Journal of Clinical Oncology. 37 (15_suppl) e16591. doi:10.1200/JCO.2019.37.15_suppl.e16591. ISSN 0732-183X. S2CID 190909472.

NT5E (English Wikipedia)

doi.org (Global: 2nd place; English: 2nd place)

ensembl.org (Global: 630th place; English: 326th place)